Responding to coordinated, consistent advocacy from ASN and other proponents of medical research funding, Congress and President Trump have passed and signed into law a spending bill that increases funding for the National Institutes of Health (NIH) by $3 billion in 2018—an 8.8% increase over 2017 funding levels. The legislation received strong bipartisan support, passing the House 256-167 and the Senate 65-32.
The New York State Nurses Association “voted overwhelmingly in favor of the latest contract offer from Fresenius Medical Care” which provides NYSNA workers with “increased pay and protects their employer-paid union pension and health funds”.
Eric Smith, the area director for NYSNA stated that the biggest win “was the inclusion of nurses’ voices on issues critical to patients’ care”.
“’This new contract ensures safe staffing, allows us to retain and attract the best of the best with fair benefits, and gives us a voice in how we care for our patients,’ said Gloria O’Neil, a registered nurse who works in a Fresenius Brooklyn clinic”.
The American Hospital Association sent a letter on June 13th, 2017 to the Centers for Medicare & Medicaid Service (CMS) requesting that the agency discontinue using the star ratings program, which AMA characterized as “deeply flawed” and as a source of regulatory burden on hospitals, health systems, and patients. AMA's main goal in issuing this letter is to provide regulatory relief for its stakeholders.
It’s been revealed ahead of the November announcement at the American Heart Association (AHA) in Anaheim, that the new guideline for blood pressure target will be 130/80 mm Hg.
“The last ‘official’ U.S. hypertension guideline was JNC 7, published in 2003. That guideline established a target systolic blood pressure of less than 140 mm Hg. (For people with diabetes or kidney disease, the target was even lower, less than 130 mm Hg.)”
Founded in 2018, KidneyX is a patient centered solution designed to reduce the specific barriers that hinder innovation in the prevention, diagnosis, and treatment of kidney diseases, and catalyze private sector involvement in ways that are not currently addressed by the public and private sectors. KidneyX will initially focus on the development and commercialization of next-generation dialysis products, and will later expand to include diagnostics, other devices, medications, and patient-centered tools to more effectively and efficiently manage kidney diseases.
Although the NIH budget has increased, none of the additional funds go to NIDDK. Limited funding means limited innovation. "The story of cancer, heart disease and HIV/AIDS is clear. Researchers go where the dollars are and funding increases drives innovation" says Chip Brosius, ASN Research Advocacy Committee Chair.